 Moneycontrol.com |
Glenmark starts phase IIb human trials of molecule
mydigitalfc.com Glenmark is positioning Revlimast as a treatment for chronic inflammatory disorders such as asthma and rheumatoid arthritis. Rheumatoid arthritis and asthma drugs are estimated to have a market in excess of $20 billion each. … Glenmark starts Phase-IIb human trials of Revamilast molecule Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule … |
View full post on asthma – Google News